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Posterior reversible encephalopathy 
syndrome (PRES) induced by intrathecal 
methotrexate administration in a patient 
with acute lymphoblastic leukaemia
AbStRAct
A patient with B-cell precursor acute lymphoblastic leukaemia was diagnosed with posterior reversible encepha-
lopathy syndrome (PRES) after an intrathecal administration of methotrexate during induction chemotherapy. 
PRES presented with headache, epilepsy, unconsciousness, blurred vision, hypertension, and vomiting. Also, 
characteristic lesions of the central nervous system were revealed by magnetic resonance imaging of the head, 
especially in the white matter of the posterior lobes. 
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Introduction
Posterior reversible encephalopathy syndrome 
(PRES) is a disease characterised by headaches, 
epileptic seizures, disorders of consciousness, arterial 
hypertension, and disturbances of vision [1, 2]. The 
symptoms are associated with vasogenic, reversible, 
focal brain oedema, mainly within the white matter. 
The lesions usually affect the posterior areas of the 
brain, the frontal lobes, cerebral cortex, and brainstem. 
With the application of magnetic resonance imaging 
(MRI), PRES is increasingly diagnosed as a com-
plication accompanying the treatment of childhood 
cancers, especially secondary to acute lymphoblastic 
leukaemia (ALL) [3]. 
case presentation
A 10-year-old patient diagnosed with ALL 
B-common, without initial CNS involvement, clas-
sified in the group of intermediate risk (IR), started 
induction chemotherapy according to the ALL IC 
BFM 2009 protocol. Two days after the first intrathe-
cal administration of 12 mg of methotrexate (MTX), 
during prednisolone prephase (60 mg/m2) the patient 
complained about headaches, hypertension, vomiting, 
and loss of consciousness [4]. Following the adminis-
tration of antiepileptic drugs (clonazepam, valproic 
acid), the boy remained mentally unresponsive, but 
with preserved reactions to pain stimuli and a sluggish 
pupillary response to light. An MRI scan revealed 
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Figure 1. MRI examination (after the first PRES episode): axial scan, FLAIR sequence — hyperintense lesions in cortico-subcortical 
areas (A); axial scan, T1 sequence after a contrast an enhancement of subcortical white matter can be observed (B)
increased signal intensity on T2-weighted and FLAIR 
sequences in the cortical and subcortical regions of 
the occipital lobes, in the posterior temporal and 
parietal lobes and apical sections of the frontal lobes 
(particularly the left lobe) and within the cerebellar 
hemispheres. The areas showed discrete enhancement 
following contrast medium administration. The above 
MRI features were interpreted as oedematous/in-
flammatory lesions or encephalopathy secondary to 
ALL (Fig. 1).
During the days following the first epileptic sei-
zure, the patient’s hypertension persisted together 
with other symptoms including bradycardia, head-
aches, and vision disturbances (double vision, distur-
bances of colour vision, blurred near vision, “misty” 
vision, spots before the eyes). Furthermore, the pa-
tient experienced another seizure episode manifested 
as a focal epileptic event — tremor in the right leg. 
Five days after second dose of intrathecal adminis-
tration of MTX (on day 12 of induction according to 
ALLIC-BFM 2009) and implementation of vincristine 
1 × 1 mg/m2/day, daunorubicin 1 × 30 mg/m2/day, and 
L-asparaginase 5000 IU/m2/day, the patient presented 
bilateral loss of vision. A subsequent computed to-
mography scan of the head revealed more prominent 
and slightly more extensive hypodense lesions, and 
an MRI scan showed an exacerbation of previously 
identified lesions. 
Because of the patient’s epileptic seizures, chemo-
therapy was postponed by six days after the first epileptic 
episode and by 11 days after the second ones. After the 
patient’s general condition was stabilised, chemotherapy 
was continued from day 33 of treatment. Intrathecally 
administered MTX was replaced by cytarabine at a dose 
of 30 mg.
A follow-up MRI scan performed two months later 
demonstrated a marked regression of lesions manifest-
ing as a reduction of the extent of hyperintense areas 
within the cortical and subcortical regions of the oc-
cipital lobes, the posterior temporal and parietal lobes, 
and the apical sections of the frontal lobes. The areas 
were not enhanced after the contrast medium admin-
istration (Fig. 2). 
Summary
Methotrexate is one of the main cytostatic drugs 
belonging to the class of antimetabolites used in the 
treatment of ALL. The neurotoxic activity of MTX 
can present as vomiting, disorders of consciousness, 
photophobia, and vision disturbances. MTX-induced 
neurotoxicity has been classified in the literature as sud-
den, acute/subacute, and chronic [5]. A similar temporal 
correlation between the time of the administration of 
MTX and the development of symptoms specific to 
PRES was observed in our patient.
The clinical and radiological features of PRES are 
non-specific, so other conditions must also be consid-
ered. It is necessary to rule out ischaemic stroke and 
intracranial haemorrhages which produce a range of 
radiological (CT) findings and clinical symptomatology 
similar to PRES. Consequently, establishing the final 
diagnosis requires an MRI scan to visualise hyperdense 
foci and densities of white matter. In uncertain cases, 
the decisive examination proving the diagnosis can be 
MRI angiography [3]. Depending on the location of 
lesions identified by MRI, PRES can be divided into 
several subtypes — with lesions in the occipital, frontal, 
parietal, and temporal lobes, and in the brainstem 
and cerebellum, dominated by vascular oedema in the 
frontal sulcus region, involving only the occipital and 
parietal lobes (“classic” PRES), and the most com-
mon variant, the so-called “asymmetric” PRES, with 
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Figure 2. MRI examination (two months after the first PRES episode) — axial scan, FLAIR sequence — a slight hyperintense 
lesions of cortico-subcortical areas (A); axial scan, T1 sequence after contrast — no enhancement of subcortical white matter (B)
a partial combination of all the subtypes referred to 
above [3]. In the subtype presenting with brainstem 
and cerebellar oedema, the diagnostic process should 
always rule out brain herniation. A similar radiological 
manifestation also occurs in cases of cerebrovascular 
thrombosis and primary vasculitis. In addition, since 
the clinical picture of patients may create reasonable 
grounds to suspect meningitis, cytological and micro-
biological analysis of cerebrospinal fluid is necessary. 
Similar symptoms may occur in rare genetic diseases 
including CADASIL and MELAS syndromes, and may 
also accompany Creutzfeldt-Jakob disease, progressive 
multifocal leukoencephalopathy, or leukoaraiosis [3]. 
In the case of our patient, we performed differential 
diagnostics: blood and cerebrospinal laboratory tests, 
blood and cerebrospinal fluid culture was made, PCR 
tests for viral and microbiological infections to exclude 
neuroinfection and ALL involvement of the CNS, CT 
scans of the head to rule out stroke or haemorrhage, 
and as the next step MRI and eye examination was 
made. ALL of this research confirmed the diagnosis 
of PRES.  
The treatment of PRES is largely limited to the 
management of symptoms. Patients with PRES are given 
anticonvulsants as well as hypotensive, antiedematous 
drugs and analgesics. The primary goal of therapy is to 
reduce the severity of syndromes. The patient described 
in the present study also received broad-spectrum antibi-
otic therapy and antiviral treatment due to preliminary 
suspicion of neuroinfection. The need to continue the 
treatment of the underlying condition (ALL) in our pa-
tient necessitated a change in the therapeutic approach. 
To avoid toxicity induced by intrathecal administered 
MTX, the drug was replaced by another cytostatic 
— cytarabine and prednisone.
The continuation of treatment of ALL in accordance 
with the therapeutic regimen, as well as compliance with 
the time schedule, are also key prognostic factors for 
predicting the curing of ALL. 
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